Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March...
March 08 2018 - 8:04AM
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating, chronic neuromuscular
and neurological diseases, today announced that it will release
fourth quarter and year-end 2017 financial results after market
close on Wednesday, March 14, 2018. Further, Catalyst management
will host an investment-community conference call at 8:30 a.m.
EDT on Thursday, March 15, 2018 to discuss the financial
results and to provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (877) 407-8912 for domestic and Canadian callers or
(201) 689-8059 for international callers. Those interested in
listening to the conference call live via the internet may do so by
visiting the Investors page of the company's website
at www.catalystpharma.com and clicking on the webcast
link on the Investors home page.
A webcast replay will be available on the Catalyst website for
30 days following the call by visiting the Investor page of the
company's website at www.catalystpharma.com.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused
on developing and commercializing innovative therapies for people
with rare debilitating, chronic neuromuscular and neurological
diseases, including Lambert-Eaton myasthenic syndrome (LEMS),
congenital myasthenic syndromes (CMS), MuSK antibody positive
myasthenia gravis, and infantile spasms. Firdapse® has received
Breakthrough Therapy Designation from the U.S. Food and Drug
Administration (FDA) for the treatment of LEMS and Orphan Drug
Designation for LEMS, CMS and myasthenia gravis. Firdapse is the
first and only approved drug in Europe for symptomatic treatment in
adults with LEMS.
Catalyst is also developing CPP-115 to treat refractory
infantile spasms. CPP-115 has been granted U.S. Orphan Drug
Designation for the treatment of infantile spasms by the FDA and
has been granted E.U. Orphan Medicinal Product Designation for the
treatment of West syndrome by the European Commission. In
addition, Catalyst is developing a generic version of Sabril®
(vigabatrin).
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements involve known and unknown risks and
uncertainties, which may cause Catalyst's actual results in future
periods to differ materially from forecasted results. A number of
factors, including those factors described in Catalyst's Annual
Report on Form 10-K for the fiscal year 2016 and its other filings
with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024